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1. Introduction
Most treatments for cancer, such as surgery, radia-
tion therapy or chemotherapy, usually attack the 
cancer itself. However, most of these treatments 
also attack not only attach to the cancer cells, but 
also normal cells of the body, causing side effects. 
Recently, evidence has been accumulating that 
closely connects the immune system with antitumor 
defense mechanisms in a multistage process includ-
ing tumorigenesis, invasion, growth and metastasis 
[1]. A number of natural herbal medicines including 
Traditional Oriental medicine are believed to show 
marked antitumor and antimetastatic effects while 
possessing immunomodulating properties and low 
toxicity for normal tissues [2−4]. Mushroom ex-
tracts have been of significant interest as dietary 
supplements based on theories that they enhance 
immune function and promote health. To some ex-
tent, selected mushrooms have been shown to have 
stimulatory action on immune responsiveness, par-
ticularly when studied in vitro. However, despite 
their widespread use for potential health benefits, 
there is a surprising paucity of epidemiological stud-
ies and experimental studies that address the 
biolog ical actives of mushrooms after oral adminis-
tration to animals or humans [5,6]. Numerous stud-
ies have demonstrated that certain components 
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present in dietary mushrooms have been responsi-
ble for the modulation of cellular and phenotypic 
expression of cytokines and their cognate recep-
tors, illustrating the reason why mushrooms are 
used as cancer therapeutic agents [7−9].
The main purposes of this research are to inves-
tigate the antitumor and immunomodulating effects 
of mushrooms. As preparatory tasks, an in vitro XTT 
assay (colon26-L5) and spleen proliferation assay 
utilizing several complex types of well-known tradi-
tional edible mushrooms were conducted to screen 
a group of mushrooms with significant antitumor and 
immunomodulating effects. As a results, Armillaria 
mellea, Grifola frondosa, Garnoderma frondosa, 
Codyceps militaris, Hericium erinaceus, Coriolus 
versicolor, Agaricus Blazei and Lycium Chinense 
Miller (LM) were selected. In this study, the complex 
of water extracts from those selected mushrooms, 
named M8, has been investigated. Specifically, the 
effect of oral administration of this prepared pre-
scrip tion on experimental lung metastasis of murine 
colon26-L5 cells was investigated and clarified its 
antimetastatic mechanism with respect to its immu-
nomodulating activities.
2. Materials and Methods
2.1. Prescription
Dried mushrooms, Armillaria mellea 3, Grifola 
frondosa 3, Garnoderma frondosa 5, Codyceps mil-
itaris 5, Hericium erinaceus 5, Coriolus versicolor 3, 
Agaricus Blazei Murill 3 and LM 3 were obtained 
from Dunsan Oriental Hospital (Daejeon, Korea). 
One hundred grams of mushrooms were washed 
several times with distilled water, soaked in 1.5 L 
of pyrogen-free water for 2 hours, and then boiled 
for 2 hours. Solid particles and aggregates were 
removed by centrifugation at 3,000 × g for 30 min-
utes and the supernatants were lyophilized. Finally, 
26.35 g of the lyophilized water extract was ob-
tained and used in this experiment. The general 
chemical composition of this prescription was ana-
lyzed in triplicate according to the methods of the 
Association of Official Analytical Chemists [10]. 
For the high-performance thin-layer chromatogra-
phy (HPTLC) analysis, beta glucan (10 mg/mL 50% 
MeOH β-D-(1,3)-(1,6)-glucan), pachyman (100 mg/
mL MeOH β-D-(1,3)-glucan) and M8 were dissolved 
in HPLC-grade methanol and applied to the pre-
washed silica gel 60 F254 HPTLC plates (size 
10 × 10 cm; thickness of the silica gel 0.2 mm; Merck, 
Darmstadt, Germany) with an automated applicator 
(Linomat IV, CAMAG, Merck KGaA, Germany). The 
samples were then separated (migration distance 
75 mm) using HPLC-grade chloroform/methanol/
water/formic acid (48:48:2:2). The migrated com-
ponents were visualized at 254 nm using Reprostar 3 
with a digital camera (CAMAG, Germany).
2.2. Cell cultures
The metastatic cell line of colon26-L5 carcinoma 
cells were maintained as monolayer cultures in 
RPMI-1640 medium (GIBCO BRL, Life Technologies 
Inc., NY, USA) supplemented with 10% fetal bovine 
serum (FBS; INC Biomedicals Inc., CA, USA). Colon26-
 L5 cells were collected by brief treatment with 
EDTA, and then used for the experiments. All cul-
tures were maintained at 37ºC in a humidified 
atmosphere of a 5% CO2/95% O2 air.
2.3. Animals
Six-week-old, specific-pathogen-free female BALB/c 
mice were purchased from Daehan Biolinks (Korea). 
The mice were maintained under specific pathogen-
free conditions and used according to institutional 
guidelines. The experiment was divided into three 
groups containing six mice in each group. The groups 
were: control, 50 mg/kg M8 treated and 200 mg/kg 
M8 treated.
2.4.  Assay for experimental lung 
metastasis of colon26-L5 
carcinoma cells
Log-phase cell cultures of colon26-L5 cells were 
harvested with 0.05% EDTA in phosphate-buffered 
saline (PBS), washed three times with serum-free 
RPMI, and resuspended at appropriate concen-
trations in RPMI. In experimental lung metastasis 
assays, six BALB/c mice per group were given an in-
travenous injection of colon26-L5 cells (2 × 105 cells/
200 mL). Fifteen days later, the mice were sacri-
ficed and the lungs were fixed in Bouin’s solution. 
The lung tumor colonies were investigated and the 
lung weight was measured. M8 was administered 
orally to the mice at a dose of 50 mg/kg and 
200 mg/kg for 12 days starting on day 3 after tumor 
inoculation.
2.5.  Preparation of mouse splenocytes 
and peritoneal exudate cells
Splenocytes were obtained by passing pieces of 
spleen through a stainless mesh, treated with a hy-
potonic solution to lyse erythrocytes, and washed 
three times with PBS. The viability of the splenocyte 
was more than 95%, as assessed by the trypan blue 
dye exclusion method. Whole splenocytes were 
suspended in RPMI-1640 medium supplemented with 
10% FBS and then used for experiments.
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2.6.  Splenocyte proliferation assay in vitro
For the splenocyte proliferation assay, M8 was ad-
ministered orally to BALB/c mice at appropriate 
doses for 2 weeks and splenocytes were obtained 
1 day after the last administration. Splenocytes (1 × 
105 cells/100 mL) suspended in RPMI-1640 medium 
supplemented with 10% FBS were cultured in 96 well 
U-bottom culture plates with or without concana-
valin A (Con A; Sigma, Chemical Co., St. Louis, MO, 
USA) or lipopolysaccharide (LPS; Sigma) for 48 hours 
at 37ºC. This assay was performed using triplicate 
cultures. XTT assay (Sigma) was performed to mea-
sure cell proliferation.
2.7. FACS analysis
Isolated cells from spleen were stained with fluores-
cein isothiocyanate (FITC)- and phycoerythrin (PE)- 
conjugated monoclonal anti-CD3, CD19, CD4, CD8, 
MAC-1, and NK1.1 antibodies (Becton-Dickinson, 
CA, USA) in PBS for 20 minutes at 4ºC. Stained 
cells were analyzed on flow cytometry (FACSCalibur; 
Becton-Dickinson) using Cell Quest software. Differ-
entiation of lymphocytes was determined using flow 
cytometric analysis of light scatter chamber char-
acteristics relating size and granulation. Two-color 
flow cytometry was then performed to calculate the 
percentages of CD3, CD19, CD4, CD8, Mac-1, and 
NK1.1 positive cells in a subset of lymphocytes.
2.8. Induction of cytokine production
Interferon (IFN)-γ and interleukin (IL)-4 levels in 
culture supernatants were evaluated using specific 
ELISA kits (BD Pharmingen, CA, USA) according to 
the manufacturer’s instructions. Cell-free super-
natant was prepared as follows. Splenocytes (1 × 
106 cells/well) were prepared as described above 
and then cultured in 24 well culture plates with or 
without various concentrations of Con A for 24 hours 
at 37ºC. The cell-free supernatant was collected 
from each well and stored at −80ºC until the ELISA 
assay.
2.9. Statistical analysis
Representative data from each experiment are 
presented as mean ± SD, as described in the figure 
legend.
3. Results
3.1. HPTLC analysis
For quality control of the tested samples, HPTLC-
based fingerprinting was performed using the 
CAMAG Application System (Muttenz, Switzerland) 
as follows. M8, β-D-(1,3)-(1,6)-glucan and pachy-
man were dissolved in 90% HPLC-grade methanol 
and applied to a pre-washed silica gel 60 F254 HPTLC 
plate (10 × 10 cm, 0.2 mm thick silica gel, Merck, 
Darmstadt, Germany) with an automated applica-
tor (Linomat IV, CAMAG, Muttenz, Switzerland). The 
samples were then separated (migration distance: 
60 mm) using HPLC grade n-butanol/methanol/
water (50:25:20). Thereafter, glucose-specific stain-
ing with aniline-diphenylamine-phosphoric acid or 
protein-specific staining with ninhydrin reagent 
UV 254 nm
i ii iii a b c i ii iii a b c
After derivatization under white light RTBA
Figure 1 M8, β-glucan and pachyman were dissolved in 90% HPLC-grade methanol and applied to a prewashed silica 
gel 60 F254 HPTLC plate. M8 (2 or 4 mL of a 50 mg/mL solution) and 2 μL β-D-(1,3)-(1,6)-glucan (10 mg/mL) were sepa-
rated (migration distance 60 mm) using HPLC-grade n-butanol/methanol/water (50:25:20). Images were visualized at 
UV 254 nm (A) or under white light after staining with aniline-diphenylamine-phosphoric acid (B).
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was separately performed. The developed plate 
was visu alized at 254 nm using a Reprostar 3 Digital 
Camera System (CAMAG; Figure 1A). Analysis of 
carbohydrate using HPTLC showed that β-glucan 
and pachyman were the major components of M8 
(Figure 1A, B).
M8, β-glucan and pachyman were dissolved in 
90% HPLC-grade methanol and applied to a pre-
washed silica gel 60 F254 HPTLC plate. M8 (2 or 4 mL 
of a 50 mg/mL solution) and 2 μL β-D-(1,3)-(1,6)-
glucan (10 mg/mL) were separated (migration dis-
tance 60 mm) using HPLC-grade n-butanol/methanol/
water (50:25:20). Images were visualized at UV 
254 nm (A) or under white light after staining with 
aniline-diphenylamine-phosphoric acid (B).
3.2.  Effect of M8 on experimental 
lung metastasis
We first examined the effect of oral administration 
of M8 on lung metastasis caused by the intravenous 
injection of colon26-L5 carcinoma cells. The lung 
weight was measured on day 15 after tumor inocu-
lation. Figure 2A shows that the oral administra-
tion of M8 for 12 consecutive days from 3 days after 
tumor inoculation attenuated the increase in lung 
weight in a dose-dependent manner in the range 
from 50 to 200 mg/kg/day. The administration of M8 
did not show any apparent side effects, such as a 
decrease of body weight shown at Figure 2B. These 
results indicate that M8 is effective in preventing 
experimental lung metastasis of colon26-L5 cells.
Female BALB/c mice (n = 6) were inoculated 
intravenously with colon26-L5 cells (2 × 105 cells/
mice). M8 Prescription at the indicated doses was 
administered orally for 12 consecutive days from 
day 3 after tumor inoculation. 15 days after tumor 
inoculation, mice were sacrificed and lung weight 
was measured.
The body weight of all the living mice (n = 6) 
were measured and there was no statistical differ-
ence between the groups.
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Figure 2 (A) Female BALB/c mice (n = 6) were inoculated intravenously with colon26-L5 cells (2 × 105 cells/mice). 
M8 prescription at the indicated doses was administered orally for 12 consecutive days from day 3 after tumor inoculation. 
15 days after tumor inoculation, mice were sacrificed and lung weight was measured. (B) The body weight of all the 
living mice (n = 6) were measured and there was no statistical difference between the groups.
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Figure 3 Female BALB/c mice were administered M8 
orally for 2 weeks. One day after the last administration, 
mice were sacrificed and the splenocytes (1 × 105 cells/
well) suspended in RPMI-1640 medium supplemented 
with 10% FBS were cultured with or without Con A or LPS 
for 48 hours. XTT assay was conducted to evaluate cell 
proliferation. The data represent the mean ± S.D. *p < 0.05 
as compared with control group.
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3.3.  Effect of M8 on the proliferation 
of splenocytes
To clarify the biological properties of M8, we investi-
gated the mitogenic responses of mouse spleen 
cells after oral administration of M8. Splenocytes 
obtained from the control group or prescriptions-
treated group were cultured with or without T cell 
mitogen (Con A) or B cell mitogen (LPS) for 48 hours. 
Figure 3 shows that treatment with M8 resulted in 
a significant increase of T cell and B cell mitogenic 
stimuli.
Female BALB/c mice were administered M8 orally 
for 2 weeks. One day after the last administration, 
mice were sacrificed and the splenocytes (1 × 105 cells/
well) suspended in RPMI-1640 medium supplemented 
with 10% FBS were cultured with or without Con A or 
LPS for 48 hours. XTT assay was conducted to evalu-
ate cell proliferation. The data represent the mean ± 
S.D. *, p < 0.05 as compared with control group.
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Figure 4 Female BALB/c mice were orally administered M8 for 2 weeks. One day after the last administration, mice 
were sacrificed and the splenocytes (1 × 105 cells/well) were stained with FITC- and PE-conjugated monoclonal anti-
CD3, CD19, CD4, CD8, Mac-1 and NK1.1 antibodies. Stained cells were analyzed on flow cytometry using Cell Quest 
Software. A representative image of whole lymphocytes sorted using light scatter is shown.
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3.4.  Phenotypic characterization 
of lymphocytes by M8
The next step was performed with flow cytometric 
analysis to examine lymphocyte differentiation 
caused by M8. Shown in Figure 4, the population of 
CD3, CD19, CD4 and CD8 positive cells was increased 
in a dose dependent fashion amongst M8 groups. 
However, no significant results from the population 
of Mac-1 and NK1.1 positive cells were observed.
Female BALB/c mice were orally administered 
M8 for 2 weeks. One day after the last administra-
tion, mice were sacrificed and the splenocytes 
(1 × 105 cells/well) were stained with FITC- and PE-
conjugated monoclonal anti-CD3, CD19, CD4, CD8, 
Mac-1 and NK1.1 antibodies. Stained cells were ana-
lyzed on flow cytometry using Cell Quest Soft ware. 
A representative image of whole lymphocytes 
sorted using light scatter is shown.
3.5. Effect of M8 on cytokine production
The next examination determined whether admin-
istration of M8 could induce the production of Th1-
type and Th2-type cytokines in splenocytes of 
M8-treated mice. Shown in Figure 5, splenocytes 
from untreated control mice and M8-treated mice 
did not show any significant difference in cytokine 
production expressing both IFN-γ and IL-4 without 
Con A stimulation. When splenocytes were incu-
bated with Con A for 24 hours, detectable changes 
of cytokine production were found in the cell-free 
supernatant. The oral administration of M8 resulted 
in a significant enhancement of IFN-γ production as 
compared with that in untreated controls. Moreover, 
M8 resulted in a significant increase of IL-4 pro-
duction. Thus, oral administration of M8 may lead 
predominantly to the production of Th1 and 2 type 
cytokines.
Female BALB/c mice were administered M8 orally 
for 2 weeks. One day after the last administration, 
mice were sacrificed and splenocytes (1 × 106 cells/
well) suspended in RPMI-1640 medium supplemented 
with 10% FBS were cultured with or without Con A 
for 24 hours. After the termination of culture, the 
cell-free supernatant was collected and the amount 
of IFN-g and IL-4 was measured by ELISA kits. The 
data represent the mean ± S.D. *p < 0.05 as compared 
with control group.
4. Discussion
Herbal remedies, specified mixtures of dried plant 
materials, have been utilized empirically. As an al-
ternative cancer therapy, Korean traditional medi-
cine has attracted a great deal of attention due to 
its low toxicity [11−13].
Mushrooms, especially, are extensively used as 
invigorants and have been used in Asian countries 
to enhance human immunity. A variety of different 
mushroom species have been investigated and there 
are now more studies addressing the oral adminis-
tration of mushroom extracts as well as semi-puri-
fied and purified polysaccharides [14,15].
Mushroom polysaccharides prevent oncogenesis, 
show direct antitumor activity against various allo-
geneic and syngeneic tumors, and prevent tumor 
metastasis. Polysaccharides from mushrooms do 
not attack cancer cells directly, but produce their 
antitumor effects by activating different immune 
responses in the host. The antitumor action of poly-
saccharides requires an intact T-cell component as 
their activity is mediated through a thymus-
depend ent immune mechanism [16].
At the end of the 1970s, mushroom research fo-
cused largely on cancer, and recently, researchers 
reported that a large variety of mushrooms have 
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Figure 5 Effect of oral administration of M8 on production of IFN-γ and IL-4 from splenocytes.
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been found to play important roles in an antitumor 
function [17].
In Korea, complex mushroom extracts are also 
popular as cancer treatments. Based on traditional 
literature, we have decided to investigate the 
efficacy and mechanism of several complex types 
of well-known traditional edible mushrooms. The 
first step was to gather the widespread popular 
prescriptions of complex mushroom extracts and 
summarize them. The next step was to conduct 
in vitro XTT assays (colon26-L5) and spleen pro-
liferation assays to screen for immunoenhancing 
and antitumor effects. From this, the resulting 
water extracts from several mushrooms (Armillaria 
mellea, Grifola frondosa, Garnoderma frondosa, 
Codyceps militaris, Hericium erinaceus, Coriolus 
versicolor, Agaricus Blazei Murill) along with LM 
(named as M8) resulted in producing a significant 
effect.
Mushroom polysaccharides are known to stimu-
late natural killer (NK) cells, T-cells, B-cells and the 
macrophage-dependent immune system response 
[16]. The immunomodulating action of mushroom 
polysaccharides is especially valuable as a means 
of prophylaxis, prevention and co-treatment with 
chemotherapy. The potential use of medicinal 
mushrooms for disease prevention and treatment 
is an expanding target for research into the health 
benefits of mushrooms and the recent interest in 
research on mushrooms extracts. For these reasons, 
there have been various reports and experiments 
with mushrooms [18].
Armillaria mellea extract has significant prop-
erties to activate macrophages and NK cells by 
promoting related cytokines like IL-1, IL-2 and 
IFN-γ gene expression [19]. Maitake D-Fraction, 
extracted from Grifola frondosa, has been re-
ported to exert its antitumor effect in tumor-bear-
ing mice by enhancing the immune system through 
activation of macrophages, T cells and NK cells 
[20]. Fruit body and liquid-cultured mycelium of 
these mushrooms also have been reported to con-
tain useful antitumor polysaccharides from various 
fractions. These polysaccharides have been identi-
fied as many types of glucans (e.g. β-1, 6- and β-1, 
3-) [21−23]. Wide varieties of applications of β-
glucan have been reported, including thickening 
and stabilizing agents in chemical industries, and 
immunostimulating and antitumor agents for clini-
cal use [24−26]. Clinical studies have demonstrated 
that this glucan activates macrophages, subse-
quently increases the T-cell cascade, which means 
increasing the body’s immune defense mechanism 
[26]. The water extract of Codyceps militaris fruit-
ing bodies inhibited cancer cell proliferation by in-
ducing cell apoptosis through the activation of 
caspase-3 [27]. It can also inhibit lung metastasis 
by suppressing the effects of basic-fibrous growth 
factor via antiangiogenesis [28]. It has been re-
ported that Hericium erinaceus has cytotoxic ef-
fects on cancer cell lines, as well as nematicidal 
and antimicrobial activities [29,30]. In addition, 
we have reported that water extract of Hericium 
erinaceum induced the production of NO and IL-1β 
in rat macrophages and a macrophage like cell 
line, RAW 264.7 [31,32].
The water extract and the polysaccharide frac-
tion of Garnoderma lucidum exhibited significant 
antitumor effects in several tumor-bearing animals 
mainly through its immunoenhancing activity [33]. 
The best known commercial polysaccharopeptide 
preparations of Coriolus versicolor are polysaccha-
ropeptide Krestin and polysaccharopeptide [34]. 
Polysaccharopeptide Krestin, extracted from 
Coriolus versicolor may act to increase leukocyte 
activation and inhibit metalloproteinases and 
other enzymes involved in metastatic activity. It 
has also been further shown to have antioxidant 
capacity which may allow it to play a role as a nor-
mal tissue chemo- and radio-protector when used 
in combination with adjuvant or definitive chemo-
therapy and/or radiotherapy in the treatment of 
cancer [35]. Polysaccharides from Agaricus blazei 
have antitumor activity against Sarcoma 180 and 
the structure includes h-1, 6-glucopyranosyl resi-
dues [36]. Agaricus blazei extract, mainly (14)-a-D 
glucan with (16)-h branching, has selective tumori-
cidal activity mediated via NK cell activation and 
apoptosis [37].
The mushroom Agaricus blazei has also been 
reported to contain an antitumor glucan with a 
β-(16) backbone [38]. In addition, an α-1,6- and 
α-1,4-glucan complex [39] and a glucomannan with 
a main chain of β-1,2-linked D-mannopyranosyl 
residues have been isolated from this mushroom 
and found to inhibit tumorigenesis [40]. The last 
herb al medicine, which is not a mushroom, in the 
M8 extract is LM. In previous studies polysaccharide 
water extract components from LM have shown that 
it can enhance immune function [41,42], protect li-
ver damage [43], reduce the side effects of chemo-
therapy and radiotherapy [44,45] and act against 
cancer [42,46,47]. In another study, LM could acti-
vate transcription factors NFAT and AP-1, induce 
IL-2 and IFN-γ gene transcription and protein pro-
duction, and stimulate T cells to produce Th1 cy-
tokines [48]. Based on each of these recent reports 
about the antimetastasic and immunomodulating 
activity of these mushrooms, we have produced M8.
In the present study, oral administration of M8 
resulted in a significant, dose-dependent inhibi-
tion of lung metastasis after intravenous injection 
of colon26-L5 cells (Figure 2), without causing any 
severe side effects such as decreased body weight. 
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These outcomes indicate that M8 is effective for 
early stage prevention of lung metastasis by colon26-
L5 cells. On the other hand, oral administration of 
M8 caused a marked augmentation of mitogen-
stimulated proliferation of splenocytes (Figure 3).
The cluster of differentiation (cluster of desig-
nation; CD) is a protocol used for the identification 
and investigation of cell surface molecules present 
on leukocytes. The CD system is commonly used as 
cell markers. This system allows cells to be defined 
based on what molecules are present on their sur-
face. These markers are often used to associate 
cells with certain immune functions or properties. 
CD molecules are utilized in cell-sorting using vari-
ous methods such as, flow cytometry [49,50].
CD4 is a glycoprotein expressed on the surface of 
T helper cells, regulatory T cells, monocytes, mac-
rophages, and dendritic cells. It is a coreceptor that 
assists the T cell receptor (TCR) to activate its T cell 
following an interaction with an antigen presenting 
cell. CD8 is a transmembrane glycoprotein that 
serves as a coreceptor for the TCR. The CD8 core-
ceptor is predominantly expressed on the surface of 
cytotoxic T cells, but can also be found on NK cells. 
CD8 keeps the T cell receptor of the cytotoxic T cell 
and the target cell bound closely together during 
antigen-specific activation [51]. CD19, is a human 
protein encoded by the CD19 gene. Lymphocytes 
proliferate and differentiate in response to various 
concentrations of different antigens. The ability of 
the B cell to respond in a specific, yet sensitive man-
ner to the various antigens is achieved with the use 
of low-affinity antigen receptors. This gene encodes 
a cell surface molecule which assembles with the 
antigen receptor of B lymphocytes in order to de-
crease the threshold for antigen receptor-depend-
ent stimulation [52].
The most two commonly-used CD molecules are 
CD4 and CD8, which are, in general, used as markers 
for helper and cytotoxic T cells, respectively. When 
defining T cells, these molecules are defined in com-
bination with CD3+, as some other leukocytes also 
express these CD molecules (some macrophages ex-
press low levels of CD4; dendritic cells express high 
levels of CD8) [50].
To examine the effect of M8 on of phenotypic 
characterization of lymphocytes, flow cytometric 
analysis was performed. CD3, CD19, CD4, and CD8 
positive cells increased in a dose dependent fash-
ion among the M8 groups. However, no significant 
results from the population of Mac-1 and NK1.1 
positive cells were obtained (Figure 4).
Th1/Th2 balance, controlled by Th1 or Th2 cells 
producing cytokines, plays an important role in an-
titumor and antimetastatic immune responses [53]. 
In the balance of Th1 and Th2 patterns of cytokines, 
Th1 cells such as IL-2 and IFN-γ are essential for the 
induction of cellular immunity, whereas Th2 cells 
producing TNF-α, IL-4, IL-5 and IL-10 play a key role 
in humoral immunity [19,54,55]. Most studies have 
shown that Th1-type cytokines increase the thera-
peutic efficacy of antitumor and antimetastatic 
responses [2]. But in other studies, Th1 cells (IL-2, 
IFN-γ) and also Th2 cells (IL-4, IL-6, IL-10) have been 
demonstrated to be useful for cancer gene therapy 
[56−59]. IL-4 has especially been known to have 
antitumor effects in murine models of malignancy 
[60,61]. At the local tumor site, Th1 cells actively 
respond to tumor cells and produce cytokines, which 
recruit other effector cells such as CD8+ T cells, 
Natural Killer T (NKT) cells and NK cells into the 
tumor tissue. Th2 cells, which are unable to enter 
tumor tissue because of a defect of adhesion mech-
anisms, are considered to activate other inflamma-
tory cells; and the products of these cells damage 
endothelial cells to induce tumor necrosis [56,57].
To confirm these results, Th1 and Th2 cytokine 
from splenocytes were measured. Oral administra-
tion of M8 resulted in the increased production of 
IFN-γ and IL-4 by splenocytes stimulated with Con 
A compared with untreated controls (Figure 5). 
These findings indicate that oral administration of 
M8 can lead to Th1-type and Th2-type immune re-
sponses. Therefore, M8 may have antitumor activi-
ties via Th1/2-type dominant immune responses.
These Th1/2 type-dominant environments at the 
tumor site may differentiate many kinds of immune 
cells that induce systemic antitumor immunity. In 
light of the fact that natural products such as mush-
rooms and plants have been used as traditional med-
icines and now are potential sources of new drugs or 
nutraceuticals, our study verified the immunostim-
ulating activity of M8. Understanding the mechanism 
of action of M8 would contribute to the understand-
ing of its biological properties and give further 
consideration to possible therapeutic applications.
In summary, the basic research of this study was 
based on the antimetastatic and immunomodulating 
activities of M8. The inhibitory effect of M8 on lung 
metastasis is associated with its immunoregulatory 
properties. M8 could be useful for preventing tumor 
metastasis because it has the advantage of possess-
ing no apparent side effects. More advanced studies 
are required in the future to explore the mechanism 
of M8.
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